Friday, July 29, 2016

Tuesday Features

Triumvira targeting cancer with customized T cells

Triumvira targeting cancer with customized T cells

President & CEO, Dr. Tony Fiorino Closely-held Triumvira Immunologics is developing a novel platform to engineer the immune system’s T cells to attack cancer using proprietary T Cell-Antigen Couplers (TACs). “TACs were designed to use the natural activation and inhibitory pathways of T cells and have the potential to outperform identically-directed... [Read more of this feature]


In conversation with Dr. Paul Lem

In conversation with Dr. Paul Lem

Dr. Paul Lem, Spartan CEO As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides fast and inexpensive sample-to-result DNA testing. One-in-three people carry genetic mutations and carrying a CYP2C19 mutation... [Read more of this feature]


Braeburn taking path as pill-free pharma company

Braeburn taking path as pill-free pharma company

Behshad Sheldon, president & CEO Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting implants and injectables that improve public health and social cost outcomes associated with drug diversion, misuse... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Oramed posts positive oral insulin data

Oramed posts positive oral insulin data

Oramed Pharmaceuticals (NASDAQ:ORMP) reported additional data from the recently concluded Phase 2b trial of its oral insulin capsule ORMD-0801 in adults with Type 2 diabetes. The data indicate a statistically significant lowering of glucose relative to placebo across several endpoints. “ORMD-0801 was safe and efficacious in reducing blood glucose... [Read more of this brief]


Feltl upgrades Novadaq to strong buy

Feltl upgrades Novadaq to strong buy

Feltl & Co. upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “strong buy” from “buy” after the company posted second quarter revenue ahead of expectations yesterday on the strength of its direct sales business. Analyst Ben Haynor maintained his price target of $15 on Novadaq. The stock was quoted $10.13, up $1.30, at mid-day Thursday. “At... [Read more of this brief]


Corey Davis joins HCW’s research team

Corey Davis joins HCW’s research team

Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals. Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending most of those years at JP Morgan and Jefferies. His therapeutic areas of focus include CNS-related disorders, such as multiple sclerosis,... [Read more of this brief]


ProMIS releases clinical results at Alzheimer’s conference

ProMIS releases clinical results at Alzheimer’s conference

ProMIS Neurosciences (TSX:PMN) released results in two presentations of its recent therapeutic developments at the Alzheimer’s Association International Conference in Toronto. “Our results presented at the AAIC meeting indicate that multiple monoclonal antibodies (mAbs) directed against five novel AD targets are viable therapeutic candidates,... [Read more of this brief]


Novadaq Q2 revenue climbs 34%

Novadaq Q2 revenue climbs 34%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago. Total direct sales in the latest quarter increased by $4.4-million, or 37%, and total partnered/international sales rose by $600,000, or 21%, compared with the same period last year. The company estimates... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+